- Home
- NAT vs CGEM Comparison
NAT vs CGEM Comparison
Compare NAT & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAT
- CGEM
- Stock Information
- Founded
- NAT 1995
- CGEM 2016
- Country
- NAT Bermuda
- CGEM United States
- Employees
- NAT N/A
- CGEM N/A
- Industry
- NAT Marine Transportation
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- NAT Consumer Discretionary
- CGEM Health Care
- Exchange
- NAT Nasdaq
- CGEM Nasdaq
- Market Cap
- NAT 516.7M
- CGEM 490.3M
- IPO Year
- NAT 1997
- CGEM 2021
- Fundamental
- Price
- NAT $2.60
- CGEM $7.54
- Analyst Decision
- NAT Hold
- CGEM Strong Buy
- Analyst Count
- NAT 2
- CGEM 4
- Target Price
- NAT $3.50
- CGEM $33.50
- AVG Volume (30 Days)
- NAT 2.4M
- CGEM 457.5K
- Earning Date
- NAT 05-28-2025
- CGEM 05-08-2025
- Dividend Yield
- NAT 13.10%
- CGEM N/A
- EPS Growth
- NAT N/A
- CGEM N/A
- EPS
- NAT 0.22
- CGEM N/A
- Revenue
- NAT $349,742,000.00
- CGEM N/A
- Revenue This Year
- NAT N/A
- CGEM N/A
- Revenue Next Year
- NAT $4.61
- CGEM N/A
- P/E Ratio
- NAT $11.68
- CGEM N/A
- Revenue Growth
- NAT N/A
- CGEM N/A
- 52 Week Low
- NAT $2.13
- CGEM $6.85
- 52 Week High
- NAT $4.40
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- NAT 55.17
- CGEM 41.51
- Support Level
- NAT $2.44
- CGEM $7.50
- Resistance Level
- NAT $2.70
- CGEM $8.97
- Average True Range (ATR)
- NAT 0.07
- CGEM 0.48
- MACD
- NAT 0.01
- CGEM -0.04
- Stochastic Oscillator
- NAT 59.62
- CGEM 2.72
About NAT Nordic American Tankers Limited
Nordic American Tankers Ltd owns and operates double hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters pursuant to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.